While several established treatments have been shown to improve outcomes in heart failure with reduced ejection fraction (HFrEF) such as beta-blockers, ACE-inhibitors and aldosterone antagonists, there is a lack of evidenced-based treatment shown to be beneficial in heart failure with preserved ejection fraction (HFpEF). There was modest improvement in NYHA class and less decline in renal function in the sacubitril-valsartan group when compared to valsartan alone. In patients with heart failure with preserved ejection fraction (HFpEF) who have NYHA II-IV symptoms, EF ≥45%, elevated natriuretic peptide levels, and evidence of structural heart disease, does the ARNI sacubitril-valsartan lead to reduced rates of total hospitalisations for heart failure and death from cardiovascular causes, when compared to valsartan alone?Īmong patients with symptomatic HFpEF (LVEF ≥45%), the combination of sacubitril-valsartan did not lead to significantly lower composite outcome of total hospitalisations for heart failure and death from cardiovascular causes, when compared to valsartan alone.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |